Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Schizophrenia is a devastating psychiatric illness that afflicts 1% of the population worldwide, resulting in substantial impact to patients, their families, and health care delivery systems. For many years, schizophrenia has been felt to be associated with dysregulated dopaminergic neurotransmission as a key feature of the pathophysiology of the illness. Although numerous studies point to dopaminergic abnormalities in schizophrenia, dopamine dysfunction cannot completely account for all of the symptoms seen in schizophrenia, and dopamine-based treatments are often inadequate and can be associated with serious side effects. More recently, converging lines of evidence have suggested that there are abnormalities of glutamate transmission in schizophrenia. Glutamatergic neurotransmission involves numerous molecules that facilitate glutamate release, receptor activation, glutamate reuptake, and other synaptic activities. Evidence for glutamatergic abnormalities in schizophrenia primarily has implicated the NMDA and AMPA subtypes of the glutamate receptor. The expression of these receptors and other molecules associated with glutamate neurotransmission has been systematically studied in the brain in schizophrenia. These studies have generally revealed region- and molecule-specific changes in glutamate receptor transcript and protein expression in this illness. Given that glutamatergic neurotransmission has been implicated in the pathophysiology of schizophrenia, recent drug development efforts have targeted the glutamate system. Much effort to date has focused on modulation of the NMDA receptor, although more recently other glutamate receptors and transporters have been the targets of drug development. These efforts have been promising thus far, and ongoing efforts to develop additional drugs that modulate glutamatergic neurotransmission are underway that may hold the potential for novel classes of more effective treatments for this serious psychiatric illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
AMPA Receptor Trafficking and Synaptic Plasticity
Malinow, R., & Malenka, R. C. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142758 · Cited by 2,588 · cited 12×
“…sorting and recycling (Steiner et al., 2005), and GRIP1, which regulates traffi cking, anchoring and endocytosis of AMPA receptors (Citri et al., 2010; Clem et al., 2010; Anggono et al., 2011), can facilitate specifi c patterns of AMPA receptor traffi cking to the PSD (Malinow and Malenka, 2002).”
BackgroundResultInfluentialTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The tripartite glutamatergic synapse is characterized by bidirectional communications between the pre-synaptic neuron, the post-synaptic neuron and the surrounding astrocytes (Araque et al., 1999; Ni et al., 2007).”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Hayashi, Y., Shi, S.-H., Esteban, J. A., Piccini, A., Poncer, J.-C., & Malinow, R. (2000) · Science · doi:10.1126/science.287.5461.2262 · Cited by 1,524 · cited 1×
“The cellular and subcellular localization and biophysical properties of the different AMPA receptors vary according to their subunit composition (Hayashi et al., 2000; Shi et al., 2001).”
BackgroundA Family of AMPA-Selective Glutamate Receptors
Keinänen, K., Wisden, W., Sommer, B., Werner, P., Herb, A., Verdoorn, T. A., Sakmann, B., & Seeburg, P. H. (1990) · Science · doi:10.1126/science.2166337 · Cited by 1,479 · cited 1×
“GluA subunits 1-4 are encoded by independent genes (Boulter et al., 1990; Keinanen et al., 1990) and assemble into homodimers in the ER, where they undergo conformational changes necessary for the proper function of the receptors Table 1.”
BackgroundNMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders
Lau, C. G., & Zukin, R. S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2153 · Cited by 1,159 · cited 1×
“NMDA receptor vesicles are initially traffi cked on microtubules by KIF17 (protein kinesin family member 17) and delivered to the dendritic spine surface membrane in a later stage by myosin cargo proteins sliding on actin fi laments (Lau and Zukin, 2007; Stephenson et al., 2008).”
Background
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286
Bukke, V. N., Archana, M., Villani, R., Romano, A. D., Wawrzyniak, A., Balawender, K., Orkisz, S., Beggiato, S., Serviddio, G., & Cassano, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207452 · Cited by 161
Rahman, T., Zavitsanou, K., Purves-Tyson, T., Harms, L. R., Meehan, C., Schall, U., Todd, J., Hodgson, D. M., Michie, P. T., & Weickert, C. S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00077 · Cited by 39
“NMDAR hypofunction is a prevailing hypothesis in the pathophysiology of schizophrenia (31) and NMDAR1 is reduced in the frontal cortex of people with schizophrenia compared to controls (32).”
BackgroundAddressing altered anticipation as a transdiagnostic target through computational psychiatry
Sepúlveda, P., Aitsahalia, I., Kumar, K., Atkin, T., & Iigaya, K. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.02.014 · Cited by 3
Metadata
- Authors
- Rubio, M. D., Drummond, J. B., & Meador-Woodruff, J. H.
- Venue
- Biomolecules and Therapeutics
- Published
- 2012-01-31
- Volume
- 20
- Issue
- 1
- Pages
- 1-18
- ISSN
- 1976-9148 (ISSN-L)
- OpenAlex
- W1991865716
- Cited by
- 83
- References
- 31
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments. https://app.cochat.ai/papers/10.4062/biomolther.2012.20.1.001
- The paper
- Rubio, M. D., Drummond, J. B., & Meador-Woodruff, J. H. (2012). Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments. Biomolecules and Therapeutics. https://doi.org/10.4062/biomolther.2012.20.1.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.